Cytyc Pays 10-Times Sales For Proxima, Breast Cancer Therapy Market Entry
This article was originally published in The Gray Sheet
Executive Summary
Cytyc likely will divest Proxima Therapeutics' GliaSite brain tumor radiation therapy system after acquiring the company for its MammoSite breast cancer system under a $160 mil. deal Feb. 9
You may also be interested in...
New Products In Brief
Fujifilm’s Aspire HD gains FDA clearance
New Products In Brief
Fujifilm’s Aspire HD gains FDA clearance
With Medicare Coverage Policy Pending, Blue Cross Finds Fault With ProDisc
A recent negative assessment of lumbar artificial disc replacement by Blue Cross Blue Shield could spell trouble for Synthes as it seeks full Medicare coverage for ProDisc